Snapshot from Jul 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Geopolitical / US Probes Merck, AbbVie China Trials
International government investigation

US Probes Merck, AbbVie China Trials

Analysis based on 18 articles · First reported Apr 20, 2026 · Last updated Jun 30, 2026

Sentiment
-40
Attention
6
Articles
18
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The investigations into Merck & Co. and AbbVie could lead to increased regulatory scrutiny and potential restrictions on U.S. pharmaceutical companies conducting clinical trials in China, impacting their research and development strategies. This event also highlights broader geopolitical tensions and national security concerns within the biotechnology sector, potentially affecting investor confidence in companies with significant operations in China.

pharmaceuticals biotechnology
Event Summary

A bipartisan group of U.S. lawmakers, led by Representative John Moolenaar of the United States — House Select Committee on the Chinese Communist Party, has launched national security investigations into Merck & Co. and AbbVie. The probes focus on their clinical trials in China, specifically in the China — Xinjiang region and at military hospitals, raising concerns about potential links to China's military capabilities and ethical lapses, including issues of informed consent and forced labor. The committee has requested detailed information from both companies by July 17. This action reflects growing U.S. government apprehension regarding China's expanding role in the biotech industry and the associated security and ethical risks for American companies. Additionally, John Moolenaar is sponsoring the Biotech Investment National Security Act, aiming to subject U.S. biotechnology investments and licensing deals in China to strict national security reviews.

Key Actions
90 United States — House Select Committee on the Chinese Communist Party opened investigations into
70 John Moolenaar sponsoring bill
Entities Involved
govactor
United States — House Select Committee on the Chinese Communist Party
The United States — House Select Committee on the Chinese Communist Party initiated national security investigations into Merck & Co. and AbbVie's clinical trials in China, demonstrating growing U.S. government concern over China's role in the biotech industry. The committee is a key actor in this event, driving the investigation and potential legislative changes.
Importance 95.0 Sentiment 0.0
stock
AbbVie
AbbVie is being investigated by the United States — House Select Committee on the Chinese Communist Party regarding its clinical trials in China, especially in China — Xinjiang and at military hospitals. This investigation highlights ethical and security risks for AbbVie and could lead to negative market sentiment and regulatory challenges.
Importance 90.0 Sentiment -30.0
stock
Merck & Co.
Merck & Co. is under investigation by the United States — House Select Committee on the Chinese Communist Party for its clinical trials in China, particularly in China — Xinjiang and at military hospitals, raising concerns about national security and ethics. This exposes Merck & Co. to potential reputational damage and regulatory scrutiny.
Importance 90.0 Sentiment -30.0
cnt
China
China is the focus of the investigation due to its clinical trial environment, which is described as having questionable ethics and potential links to its military. The investigation highlights U.S. concerns about China's biotechnology ecosystem and its alleged human rights abuses in China — Xinjiang.
Importance 80.0 Sentiment -50.0
per
John Moolenaar
John Moolenaar, a Republican Representative and chair of the United States — House Select Committee on the Chinese Communist Party, is leading the investigation into Merck & Co. and AbbVie. He is also sponsoring the Biotech Investment National Security Act to further regulate U.S. biotechnology investments in China.
Importance 70.0 Sentiment 0.0
loc
China — Xinjiang
China — Xinjiang is highlighted as the epicenter of Beijing's 'genocide' targeting Uyghurs and other ethnic and religious minorities, raising significant ethical concerns about clinical trials conducted there by Merck & Co. and AbbVie.
Importance 60.0 Sentiment -70.0
oth
Biotech Investment National Security Act
The Biotech Investment National Security Act is a proposed bill that would amend existing legislation to add biotechnology to a list of screened technologies, requiring strict national security review for outbound U.S. biotechnology deals in China. This act signifies a potential tightening of regulations affecting companies like Merck & Co. and AbbVie.
Importance 50.0 Sentiment 0.0
oth
Biosecure Act
The Biosecure Act, signed into law by Donald Trump, restricts federal agencies' business dealings with non-U.S. biotechnology companies, indicating a broader trend of U.S. government concern over foreign involvement in the biotech industry.
Importance 40.0 Sentiment 0.0
per
Donald Trump
Donald Trump signed the Biosecure Act into law, which restricts federal agencies' business dealings with non-U.S. biotechnology companies, reflecting a broader U.S. policy trend relevant to the current investigations.
Importance 20.0 Sentiment 0.0
Relationships
Merck & Co. related ↔ China
Merck & Co. related ↔ Donald Trump
China related ↔ Donald Trump
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.